Position in OCGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,371,212
-$3,458,037 QoQ
Shares Held
2,203,407
-41.6% QoQ
Ownership
0.650%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#16
of 147 holders
Holding Since
Jun 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Qube Research & Technologies Ltd holds $2,437,858,262 across 168 Biotechnology names. OCGN ranks #89 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
798,715 | $240,437,176 | |
| 2 | INSM |
INSMED Inc
|
1,682,334 | $179,370,451 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
221,607 | $138,180,828 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,454,496 | $122,254,613 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
426,336 | $104,354,262 | |
| 6 | 659,678 | $87,559,060 | |||
| 7 | TVTX |
Travere Therapeutics, Inc.
|
1,443,230 | $81,989,896 | |
| 8 | RPRX |
Royalty Pharma plc
|
1,412,112 | $79,177,119 |
All Filings in OCGN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,371,212 | 2,203,407 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $6,829,249 | 3,773,066 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $188,389 | 194,216 | Shares | Sole | 2025-08-14 | |
| 2023-12-31 | $1,467 | 2,552 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $10,470 | 26,177 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $179,223 | 330,062 | Shares | Sole | 2023-08-14 | |
| 2022-12-31 | $67,445 | 51,881 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $330,084 | 185,441 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $1,128,042 | 496,935 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||